Current Neuro-Oncology

Volume 23 Number 22
30 November 2021

Home > Publications > Current Neuro-Oncology > Volume 23, Year 2021 > Number 22, 30 November


Bauer EK, Werner JM, Fink GR, Langen KJ, Galldiks N.
Case Report: Detection of Symptomatic Treatment-Related Changes in a Patient With Anaplastic Oligodendroglioma Using FET PET.
Front Oncol. 2021 Nov 16, 2021;11:735388
. doi: 10.3389/fonc.2021.735388. PMID: 34868923. Case report.

Fu S, Piccioni DE, Liu H, Lukas RV, Kesari S, Aregawi D, Hong DS, Yamaguchi K, Whicher K, Zhang Y, Chen YL, Poola N, Eddy J, Blum D.
A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.
Sci Rep. 2021 Nov 16, 2021;11(1):22355
. doi: 10.1038/s41598-021-01707-3. PMID: 34785698. Interventional study.

Kirchner MA, Holzgreve A, Brendel M, Orth M, Ruf VC, Steiger K, Pötter D, Gold L, Unterrainer M, Mittlmeier LM, Barci E, Kälin RE, Glass R, Lindner S, Kaiser L, Maas J, von Baumgarten L, Ilhan H, Belka C, Notni J, Bartenstein P, Lauber K, Albert NL.
PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook.
Front Oncol. 2021 Nov 17, 2021;11:774017
. doi: 10.3389/fonc.2021.774017. PMID: 34869017. Laboratory investigation.

Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Viteri S, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK.
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Clin Cancer Res. 2021 Nov 17, 2022 Mar 15;28(6):1117-1126
. doi: 10.1158/1078-0432.CCR-21-2733. PMID: 34789481. Observational study.

Saran F, Welsh L, James A, McBain C, Gattamaneni R, Jefferies S, Harris F, Pemberton K, Schaible J, Bender S, Cseh A, Brada M.
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
J Neurooncol. 2021 Nov 17, 2021 Dec;155(3):307-317
. doi: 10.1007/s11060-021-03877-6. PMID: 34787778. Interventional study.

Akimoto J, Fukami S, Ichikawa M, Nagai K, Kohno M.
Preliminary Report: Rapid Intraoperative Detection of Residual Glioma Cell in Resection Cavity Walls Using a Compact Fluorescence Microscope.
J Clin Med. 2021 Nov 18, 2021;10(22):5375
. doi: 10.3390/jcm10225375. PMID: 34830662. Observational study.

Peach MS, Burke AM, Jo J, Ju AW, Yang K.
GammaTile Brachytherapy Combined With External Beam Radiation Therapy for the Treatment of a Partially Resected Secondary Glioblastoma (WHO Grade 4 IDH-Mutant Astrocytoma): Matching External Beam Dose Gradient to Brachytherapy Dose Fall-Off.
Cureus. 2021 Nov 18, 2021;13(11):e19717
. doi: 10.7759/cureus.19717. PMID: 34934580. Case report.

Pesce A, Armocida D, Paglia F, Palmieri M, Frati A, D'Andrea G, Salvati M, Santoro A.
IDH Wild-type Glioblastoma Presenting with Seizure: Clinical Specificity, and Oncologic and Surgical Outcomes.
J Neurol Surg A Cent Eur Neurosurg. 2021 Nov 18
. doi: 10.1055/s-0041-1735515. PMID: 34794192. Observational study˰

Bunevicius A, Pikis S, Kondziolka D, Patel DN, Bernstein K, Sulman EP, Lee CC, Yang HC, Delabar V, Mathieu D, Cifarelli CP, Arsanious DE, Dahshan BA, Weir JS, Speckter H, Mota A, Tripathi M, Kumar N, Warnick RE, Peker S, Samanci Y, Barnett G, Hefnawi FE, Al Sideiri G, Sheehan J.
Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study.
J Neurooncol. 2021 Nov 19, 2021;155(3):343-351
. doi: 10.1007/s11060-021-03883-8. PMID: 34797526. Observational study˰

Duchatel RJ, Mannan A, Woldu AS, Hawtrey T, Hindley PA, Douglas AM, Jackson ER, Findlay IJ, Germon ZP, Staudt D, Kearney PS, Smith ND, Hindley KE, Cain JE, André N, La Madrid AM, Nixon B, De Iuliis GN, Nazarian J, Irish K, Alvaro F, Eisenstat DD, Beck A, Vitanza NA, Mueller S, Morris JC, Dun MD.
Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.
Neurooncol Adv. 2021 Nov 19, 2021;3(1):vdab169
. doi: 10.1093/noajnl/vdab169. PMID: 34988452. Observational study.

Poon MTC, Keni S, Vimalan V, Ip C, Smith C, Erridge S, Weir CJ, Brennan PM.
Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study.
Neurooncol Adv. 2021 Nov 19, 2021;3(1):vdab171
. doi: 10.1093/noajnl/vdab171. PMID: 34988453. Observational study.

Lombardi G, Spimpolo A, Berti S, Campi C, Anglani MG, Simeone R, Evangelista L, Causin F, Zorzi G, Gorgoni G, Caccese M, Padovan M, Zagonel V, Cecchin D.
PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction.
Br J Radiol. 2021 Nov 23, 2022;95(1129):20211018
. doi: 10.1259/bjr.20211018. PMID: 34762492. Observational study.

Wang Q, Niu W, Pan H.
Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Acta Neurochir (Wien). 2021 Nov 23, 2021:1–4
. doi: 10.1007/s00701-021-05061-1. PMID: 34812950. Case report.

Shieh LT, Ho CH, Guo HR, Huang CC, Ho YC, Ho SY.
Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database.
Front Neurol. 2021 Nov 24, 2021;12:659921
. doi: 10.3389/fneur.2021.659921. PMID: 34899553. Observational study.

Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V.
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Lancet Oncol. 2021 Nov 24, 2022;23(1):53-64
. doi: 10.1016/S1470-2045(21)00578-7. PMID: 34838156. Interventional study˰

Yan P, Li JW, Mo LG, Huang QR.
A nomogram combining inflammatory markers and clinical factors predicts survival in patients with diffuse glioma.
Medicine (Baltimore). 2021 Nov 24, 2021;100(47):e27972
. doi: 10.1097/MD.0000000000027972. PMID: 34964788. Observational study.

Wang B, Zhang S, Wu X, Li Y, Yan Y, Liu L, Xiang J, Li D, Yan T.
Multiple Survival Outcome Prediction of Glioblastoma Patients Based on Multiparametric MRI.
Front Oncol. 2021 Nov 25, 2021;11:778627
. doi: 10.3389/fonc.2021.778627. PMID: 34900728. Observational study.

Chiocca EA, Gelb AB, Chen CC, Rao G, Reardon DA, Wen PY, Bi WL, Peruzzi P, Amidei C, Triggs D, Seften L, Park G, Grant J, Truman K, Buck JY, Hadar N, Demars N, Miao J, Estupinan T, Loewy J, Chadha K, Tringali J, Cooper L, Lukas RV.
Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial.
Neuro Oncol. 2021 Nov 26, 2021:noab271
. doi: 10.1093/neuonc/noab271. PMID: 34850166. Interventional study.


Luan XZ, Wang HR, Xiang W, Li SJ, He H, Chen LG, Wang JM, Zhou J.
Extracranial multiorgan metastasis from primary glioblastoma: A case report.
World J Clin Cases. 2021 Nov 26, 2021;9(33):10300-10307
. doi: 10.12998/wjcc.v9.i33.10300. PMID: 34904103. Case report.

Halatsch ME, Dwucet A, Schmidt CJ, Mühlnickel J, Heiland T, Zeiler K, Siegelin MD, Kast RE, Karpel-Massler G.
In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma.
Pharmaceuticals (Basel). 2021 Nov 29, 2021;14(12):1241
. doi: 10.3390/ph14121241. PMID: 34959641. Expanded access study.

Di Bella G, Borghetto V, Costanzo E.
A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness.
Neuro Endocrinol Lett.
2021 Nov 30, 2021;42(7):464-483. PMID: 35490357. Observational study.

Hwang K, Kim J, Kang SG, Jung TY, Kim JH, Kim SH, Kang SH, Hong YK, Kim TM, Kim YJ, Choi BS, Chang JH, Kim CY.
Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open-label phase 2 study.
Cancer Med. 2021 Nov 30, 2021;11(2):371-379
. doi: 10.1002/cam4.4454. PMID: 34845868. Interventional study.

Neth BJ, Carabenciov ID, Ruff MW, Johnson DR.
Temporal Trends in Glioblastoma Survival: Progress then Plateau.
Neurologist. 2021 Nov 30, 2021;27(3):119-124
. doi: 10.1097/NRL.0000000000000393. PMID: 34855660. Observational study˰